ESR1 and breast cancer: Overexpression of EGFR and IGF-IR, lack of hormonal targeted cancer therapy, low survival rate and poor patient prognosis are hallmark features of the estrogen receptor alpha-negative (ERα-) breast cancer subtype [11–15].